Biogen Inc BIIB shares were under pressure Wednesday following the release of the biotech's first-quarter report, including the statement that Biogen's BLA filing for its Alzheimer's drug will be delayed.
Issuing an update on the regulatory filing for the Alzheimer's investigational drug it is co-developing with Eisai Co., Ltd ESALY, Biogen said it has started submitting modules of the filing.
The company said it has had formal interactions with the FDA using mechanisms such as Type C meetings.
Offering a timeline, the Cambridge, Massachusetts-based company said it is preparing for a pre-BLA meeting with the FDA that's scheduled for the summer.
Biogen said it hopes to complete the BLA filing with the FDA in the third quarter of 2020 as opposed to the initially planned timeline of early 2020.
The company resurrected its almost-dead Alzheimer's investigational drug aducanumab by announcing in October 2019 it is planning to file a BLA following a new analysis.
The sell-side has been divided over the likelihood of the drug receiving FDA approval.
Biogen reported Wednesday with first-quarter revenue of $3.534 billion, up 1% year-over-year, as revenue from its multiple sclerosis franchise climbed 8% and biosimilar revenues climbed 25%. Non-GAAP EPS rose from $6.98 in 2019 to $9.14 in 2020.
The results exceeded the consensus estimates that called for EPS of $7.73 on revenue of $3.41 billion.
Biogen shares were down 11.68% at $290.59 at the time of publication Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.